Cas No.Product NameDescription
1356962-20-3AZD3463AZD-3463 is an ALK/IGF1R inhibitor which overcomes multiple mechanisms of acquired resistance to crizotinib.
129639-79-8AbafunginAbafungin is a broad-spectrum antifungal agent with a novel mechanism of action for the treatment of dermatomycoses.
761439-42-3TAE684NVP-TAE 684 is an ALK inhibitor with an IC50 between 2 and 10 nM.
356559-20-1SB 525334SB525334 is a potent and selective inhibitor of TGFβ receptor I (ALK5) with IC50 of 14.3 nM, is 4-fold less potent to ALK4 than ALK5 and inactive to ALK2, 3, and 6.
1256580-46-7CH5424802CH5424802 is a potent, selective, and orally available ALK inhibitor.
446859-33-2RepSoxRepSox can efficiently replace transgenic Sox2 in the absence of VPA and cMyc, as well as in both embryonic and adult fibroblasts, we chose to further characterize E-616452 and named it RepSox, for Replacement of Sox2.
909910-43-6A 83-01A 83-01 is a selective inhibitor of TGF-β type I receptor ALK5 kinase, type I activin/nodal receptor ALK4 and type I nodal receptor ALK7 (IC50 values are 12, 45 and 7.5 nM respectively).
1197958-12-5ALK-IN-1AP26113, a dual ALK/EGFR inhibitor, is a potent and selective active inhibitor of anaplastic lymphoma kinase (ALIC) in-vitro in anaplastic large cell lymphoma (ALCL; NPM-ALK) and NSCLC (EML4-ALK) and in Karpas-299 ALCL and H3122 NSCLC xenograft models.
254750-02-2PF03491390Emricasan (IDN-6556, PF-03491390) is a potent irreversible pan-caspase inhibitor.
1032900-25-6LDK378LDK378 is a highly selective inhibitor of an important cancer target, anaplastic lymphoma kinase (ALK) .
898280-07-4XL-228 XL228 is a protein kinase inhibitor targeting IGF1R, the AURORA kinases, FGFR1-3, ABL and SRC family kinases.
1009817-63-3b-AP15b-AP15 is a specific inhibitor of the deubiquitinating enzymes Uch37 and Usp14 of the 26S proteasome.
1132935-63-7ABT333ABT-333 is an NS5B non-nucleoside polymerase inhibitor.
761438-38-4ALK inhibitor 2ALK inhibitor 2 is a novel and selective inhibitor for the ALK kinase.
1454846-35-5PF-06463922PF-06463922 is a novel, orally available, CNS-penetrant, ATP-competitive inhibitor of ALK/ROS1 with Ki of <0.02 nM, <0.07 nM, and 0.7 nM for ROS1, ALK (WT), and ALK (L1196M), respectively.
1380575-43-8LDK-378 dihydrochlorideLDK378 2Hcl (Ceritinib) is potent inhibitor against ALK with IC50 of 0.2 nM, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively.
1415560-69-8PF 02341066 hydrochlorideCrizotinib is inhibitor of the c-Met kinase and the NPM-ALK.
1351635-67-0ONO-4059 analogThe product is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor with an IC50 in the sub-nM range.
219766-25-3ANA-12ANA-12 is aTrkB receptor antagonist. ANA-12 showed direct and selective binding to TrkB and inhibited processes downstream of TrkB without altering TrkA and TrkC functions.
1108743-60-7EntrectinibEntrectinib (RXDX-101) is an oral pan-Trk, ROS1, and ALK inhibitor, with IC50 of 1.7/0.1/0.1 nM, 0.2 nM, and 1.6 nM for Trk A/B/C, ROS1, and ALK, respectively. Entrectinib, also known as RXDX-101 and NMS-E628, is an oral small molecule inhibitor of TrkA, TrkB and TrkC, as well as ROS1 and ALK, with high potency and selectivity.

First Previous Next End   Jump to  Page
Cell Cycle/Checkpoint
Angiogenesis/Tyrosine Kinase
Apoptosis Pathway
Aurora/Ksp Pathway
MAPK Pathway
Hormone Pathay
Proteases/HSP90/HSP70 Pathway
Wnt/Hedgehog/Notch Pathway
Jak/Stat Pathway
Ca/cAMP/Lipid Signaling Pathway
Neuro Signaling Pathway
TGF-beta/Smad Signaling Pathway
GPCR Pathway
Ion channel Pathway
Cytochrome P450 Pathway
Others Pathway